Triveni Bio
triveni.bio
Actively hiring
Biologics & Biosimilars
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Triveni Bio Launches with $92M Series A Financing PharmExec
Company aims to develop functional antibodies for the treatment of immunological & inflammatory disorders.
Read more
Report
Triveni Bio Raises $65 Million Series C To Expand Clinical Studies For TRIV-573
Triveni Bio announced it raised $65 million in Series C funding to support pipeline expansion and continued corporate growth. The company is a clinical-stage biotechnology company developing novel antibody treatments for immunological and inflammatory dis
Read more
Report
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
- Series C supported by premier syndicate including co-leads Ascenta Capital and Janus Henderson Investors with significant participation from Deep Track plus existing investors - - Funding enables larger Phase 2 clinical proof-of-concept trial evaluating
Read more
Report
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
- Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13) to bring a first-in-class therapeutic to patients in atopic dermatitis - - Phase 2 patient proof-of-concept study in moderate-to-severe atopic de
Read more
Report
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
Triveni Bio, Inc., a clinical-stage biotechnology company focused on developing innovative, genetics-informed antibody treatments for inflammatory and immunological (I&I) disorders, today announced the dosing of the first healthy volunteers in its Phase 1
Read more
Report
Triveni Bio doses first patient in global phase 2 proof of concept study of TRIV-509 in atopic dermatitis
Triveni Bio doses first patient in global phase 2 proof of concept study of TRIV-509 in atopic dermatitis
Read more
Report
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
- Phase 2 atopic dermatitis (AD) study advances TRIV-509, a differentiated anti-KLK5/7 antibody with the potential to deliver a new level of clinical efficacy and a convenient quarterly subcutaneous dosing option - - Oral presentation at EADV Congress 202
Read more
Report
Fierce Biotech names Triveni Bio a "Fierce 15" Biotech Company of 2025
WATERTOWN, MA - September 22, 2025 - Triveni Bio, Inc., a biotechnology company focused on developing innovative antibody treatments for inflammation and immunology (I&I) disorders, today announced that Fierce Biotech has named it as one of 2025's Fierce
Read more
Report
Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis
- Triveni Bio enters the clinic with TRIV-509 and plans to initiate two additional patient studies in the second half of 2025 - - Scientific presentations elucidate the importance of KLK5/7 in AD disease pathology and support advancement of second-generat
Read more
Report
Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
- Series B led by Goldman Sachs Alternatives with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors - - Funding will advance second-generation anti-kallikrein 5/7+IL-13 bispecific (TRIV-573) through clin
Read more
Report
Show more news